Rukan Daccak, MD
Gastroenterology · Pasadena, TXNPI 1780629840
Payments from drug & device makers
Across 206 payments — averaging $4428.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$775K
- Boehringer Ingelheim International GmbH$51K
- Eli Lilly$41K
- Janssen Research & Development, LLC$25K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$10K
- Intercept Pharmaceuticals, Inc.$5K
- plus $6K from 19 others
Across 6 payments — averaging $4187.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$25K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 52 | $775,297 |
| Boehringer Ingelheim International GmbH | 53 | $50,536 |
| Eli Lilly | 7 | $40,674 |
| Janssen Research & Development, LLC | 16 | $24,704 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $9,500 |
| Intercept Pharmaceuticals, Inc. | 2 | $5,177 |
| Bristol Myers Squibb | 4 | $3,000 |
| Conmed Corporation | 3 | $1,310 |
| Pfizer | 3 | $791 |
| AbbVie | 21 | $622 |
| Gilead | 11 | $201 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $111 |
| Madrigal Pharmaceuticals | 3 | $86 |
| QOL Medical, LLC | 5 | $54 |
| Ironwood Pharmaceuticals, Inc | 2 | $47 |
| Novo Nordisk | 2 | $43 |
| Vivus LLC | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Merck | 1 | $29 |
| Redhill Biopharma Inc. | 2 | $29 |
| Shionogi Inc | 1 | $26 |
| Romark Laboratories, LC | 3 | $24 |
| Vibrant Gastro, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Boston Scientific | 1 | $12 |
How this compares
$912,369 in reported general payments places this provider in the 95th percentile of 1,350 gastroenterology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in Pasadena
- Eric LawitzSan Antonio$59.5M
- George DuvallTyler$17.5M
- John FordtranDallas$9.9M
- Timothy RitterSouthlake$7.7M
- Parvez MantryDallas$6.4M
- Mazen NoureddinHouston$6.1M
- Nadege GunnWaco$5.7M
- Michael BrownDallas$5.5M
- James MaherHouston$5.3M
- Stephen HarrisonLive Oak$5.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.